{"id":"W2947719708","doi":"10.1200/jco.2019.37.15_suppl.9069","title":"Clinical outcomes of EGFR+ NSCLC pts treated with immune checkpoint inhibitors (ICI).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôtel-Dieu de Québec","funders":"","keywords":"Medicine; Pemetrexed; Nivolumab; Pembrolizumab; Ipilimumab; Erlotinib; Internal medicine; Oncology; Carboplatin; Atezolizumab; Lung cancer; Cancer; Chemotherapy; Immunotherapy; Epidermal growth factor receptor; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00777333,0.0002304864,0.004046259,0.0002075888,0.0000310221,0.00000642438,0.0002995319,0.0004818261,0.0002926262],"category_scores_gemma":[0.008587902,0.0001261719,0.001332587,0.0002697867,0.0007887147,0.0001274876,0.000170417,0.001987581,0.00007692588],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002579966,"about_ca_system_score_gemma":0.002416255,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001065548,"about_ca_topic_score_gemma":0.00004318049,"domain_scores_codex":[0.9922588,0.0007138268,0.005402692,0.0003007611,0.0009210029,0.0004029013],"domain_scores_gemma":[0.9890391,0.005440183,0.003306895,0.0004623933,0.001251103,0.0005003685],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0110759,0.002279548,0.950718,0.00008567076,0.002473664,0.0004384254,0.00007430218,0.000004448322,0.0004227392,0.00003126887,0.0023776,0.03001846],"study_design_scores_gemma":[0.02107341,0.04015568,0.9165014,0.0003948774,0.0005973766,0.0001531656,0.000242431,0.00001459179,0.0005357002,0.00004981385,0.02015947,0.0001221014],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9797047,0.0007074773,0.00001387228,0.01011103,0.001295313,0.0004883531,0.000003421149,0.00001527882,0.007660564],"genre_scores_gemma":[0.9931769,0.001347395,0.001628649,0.0008618379,0.0009582112,0.000004446204,0.000001823098,0.00003170043,0.001989061],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03787614,"threshold_uncertainty_score":0.9997632,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1224058409726355,"score_gpt":0.5188490254552658,"score_spread":0.3964431844826303,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}